Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
- Companies
- Company details
Active Biotech
Active Biotech AB is a Swedish biotech company focusing on the research and development of pharmaceuticals, primarily for the treatment of autoimmune / inflammatory diseases and cancer.The company in detail
Profile
Active Biotech is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. The most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune diseases and cancer as well as a novel concept for use in cancer immunotherapy (ANYARA).
Partnering strategy/interests
Active Biotech's business strategy is:
* to endeavour to attain both organic growth and growth through acquisitions and alliances
*to sign partnership agreements with external partners with a view to share risks/costs
*to achieve maximum value growth within each project through the optimal utilisation of its in-house expertise and infrastructure, as well as by seeking collaborations with strong partners at the right stage of each project
*to retain the market rights to future sales in selected European markets
*to generate income from its research collaborations, licensing activities and sales
Out-licensing
R&D
To view this information, you must subscribe to Partneringtools.
Partnerships
To view this information, you must subscribe to Partneringtools.
Deals
To view this information, you must subscribe to Partneringtools.
Latest News
To view this information, you must subscribe to Partneringtools.
Press Releases
(13th May 2008) Active Biotech advances ANYARA into Phase III clinical trial. May 13, 2008 - An interim analysis has been performed in Active Biotech AB's (OMX Nordic: ACTI) ongoing Phase II/III clinical study of ANYARA, in patients with advanced renal cell cancer. More
(15th Apr 2008) Lund, Sweden, April 15, 2008 - Active Biotech AB (OMX Nordic:ACTI) has presented results from pre-clinical studies at the 99th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, USA. More
(24th Oct 2007) Results of Clinical Phase I Study Presented at US Conference More
(10th Aug 2007) The review of Active Biotech's IND (Investigational New Drug) for the TASQ prostate cancer project has been completed by the US Food and Drug Administration (FDA). More
(26th Jul 2007) Active Biotech AB (OMX Nordic:ACTI) today announced that ANYARA has been granted Orphan Drug Status by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA). Orphan Drug designation provides a variety of incentive More
(9th Jun 2007) Active Biotech (ACTI.ST), today announced new positive clinical data from the Phase Ib study of TASQ, for the treatment of prostate cancer. More
(1st May 2007) Jerusalem, Israel and Lund, Sweden, May 1, 2007 - Teva Pharmaceutical Industries Ltd. and Active Biotech AB today announced that data from a 36-week, randomized, double-blind, placebo-controlled Phase IIb study demonstrated that an oral 0.6 mg dose o More
(13th Dec 2006) Active Biotech's Novel Cancer Treatment ANYARA Shows Pharmacological Proof of Concept after Successful Phase I Studies More
(20th Sep 2006) Active Biotech (ACTI.ST). An interim analysis of the ongoing TASQ Phase I study shows a treatment effect for all evaluated prostate cancer patients. Phase II/III studies are planned to start in year 2007. More
(7th Sep 2006) Active Biotech (ACTI.ST) publishes a new scientific paper - More
(26th Jun 2006) Active Biotech (Stockholm: ACTI.ST) presented pre-clinical results More
(5th Jun 2006) Active Biotech (Stockholm: ACTI.ST) has presented clinical results for its ANYARA project at the major ASCO annual conference (42nd American Society for Clinical Oncology Annual Meeting, June 2 - 6 2006, www.asco.org). At the conference, Active Biote More
(9th May 2006) Agreement Creates Synergistic Alliance Focused on Immune-Mediated Inflammatory Disorders More
(23rd Mar 2006) Patent application submitted regarding the mode of action for quinoline compounds More
(19th Dec 2005) Active Biotech Advances 57-57 Project With Commencement of Phase I Clinical Trial in patients More
(15th Dec 2005) Active Biotech (Stockholm: ACTI.ST), today announced that 30 patients with non-small cell lung, renal cell or pancreatic cancer have been treated with ANYARA in the Company's ongoing Phase I dose escalation study. More
(30th Sep 2005) Survival data for renal patients and the first generation (TTS CD2) of ANYARA will be presented at the NCRI (National Cancer Research Institute) conference held in Birmingham, UK, October 2-5. More
(29th Sep 2005) In an ongoing clinical Phase I study, specific tumor localization of Active Biotech's candidate drug ANYARA, has now been objectively confirmed. More
(27th Sep 2005) The safety data from Active Biotech's (Stockholm: ACTI.ST) recently concluded clinical phase II safety study shows that laquinimod, a novel oral medication for the treatment of multiple sclerosis (MS), was well tolerated also at a higher dose. More
(18th Jul 2005) The first clinical study with Active Biotech's candidate drug 57-57 against SLE (Systemic Lupus Erythematosus) has been successfully concluded. More
Senior management
To view this information, you must subscribe to Partneringtools.
Board of directors
To view this information, you must subscribe to Partneringtools.
Head office
Active Biotech
Box 724
Lund
SE-220 07
Sweden
Tel: (46) 4 619 20 00
Fax: (46) 4 619 20 50
www | email
Box 724
Lund
SE-220 07
Sweden
Tel: (46) 4 619 20 00
Fax: (46) 4 619 20 50
www | email
Contact details
Dr Peter Lando
Business Development
Business Development
Company figures
Related categories
- Industry sector
- Biotechnology / Other
- Biotechnology / Human therapeutics
- Drug delivery / Oral solid
- Drug discovery
- Pharmaceutical / Prescription
- Therapeutic target
- Gastrointestinal
- Gastrointestinal / Inflammatory bowel disease
- Genito-urinary
- Genito-urinary / Urinary / Urinary tract disorder (other)
- Genito-urinary / Gender related medicine female / Gynecological disorder (other)
- Immune related disorders
- Immune related disorders / Immune disorder (non-specific)
- Immune related disorders / Immunostimulation
- Immune related disorders / Autoimmune disease (non-specific)
- Musculoskeletal
- Musculoskeletal / Musculoskeletal disorder (other)
- Musculoskeletal / Skeletal / Arthritis (non-specific)
- Musculoskeletal / Skeletal / Rheumatoid arthritis
- Oncology
- Oncology / Kidney cancer
- Oncology / Prostate cancer
- Oncology / Breast cancer
- Oncology / Lung cancer
- Oncology / Tumor (other)
- Oncology / Cervical cancer
- Oncology / Pancreatic cancer
- Oncology / Kidney cancer / Renal cell carcinoma
- Oncology / Treatments / Chemotherapy
- Oncology / Treatments / Radioimmunotherapy
- Oncology / Stomach/Esophageal / Adenocarcinoma
- Oncology / Colorectal cancer / Rectal cancer
- Other therapeutic
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us